Rani Therapeutics Q2 FY26 net loss narrows to USD 8.42 million; revenue turns to USD 1.71 million
RANI•RT-114 study progress and timeline
RT-114 Phase 1a expansion cohort began dosing; additional data are due by end-2026, with a Phase 1b repeat-dose obesity study targeted by end-2026.
Costs decline and cash position improves
R&D spending slipped to USD 5 million from USD 5.5 million, on lower compensation and facilities, materials and supplies costs.
Cash, cash equivalents and marketable securities climbed to USD 53.4 million at June 30 from USD 43.4 million at March 31.
Q2 loss narrows as revenue turns positive
Rani Therapeutics posted a Q2 net loss of USD 8.4 million, narrowing from USD 11.2 million a year earlier.
Contract revenue rose to USD 1.7 million from no contract revenue, driven primarily by the Chugai collaboration and license agreement.
